| Place of Origin: | China |
|---|---|
| Minimum Order Quantity: | Negotiation |
| Price: | Negotiation |
| Packaging Details: | Your demand |
| Delivery Time: | Negotiation |
| Payment Terms: | D/P, D/A, L/C, T/T |
| Supply Ability: | Negotiation |
| Cas No: | 15307-81-0 | Ec No: | 630-422-6 |
|---|---|---|---|
| Name: | Diclofenac Potassium | Synonyms: | N-(2,6-Dichlorophenyl)-o-aminophenylacetic Acid Sodium Salt;sodium(o-((2,6-dichlorophenyl)amino)phenyl)acetate |
| Molecular Formula: | C14H10Cl2KNO2 | Molecular Weight: | 334.24 |
| Melting Point: | 300-330 °C | UN: | 2811 6.1 |
| High Light: | Cas No 15307-81-0,diclofenac potassium API,Cas 15307-81-0 diclofenac potassium powder |
||
Diclofenac potassium Cas No 15307-81-0; API; cardiovascular and cerebrovascular;
| Name | Diclofenac potassium |
| Synonyms | N-(2,6-Dichlorophenyl)-o-aminophenylacetic acid sodium salt;sodium(o-((2,6-dichlorophenyl)amino)phenyl)acetate |
| Molecular Formula | C14H10Cl2KNO2 |
| Molecular Weight | 334.24 |
| CAS Registry Number | 15307-81-0 |
| EINECS Number | 630-422-6 |
| Melting point | 300-330 °C |
| UN | 2811 6.1 |
Product Description:
Dichlofenac potassium is the potassium salt of dichlofenac. It is a nonsteroidal anti-inflammatory agent that can be used to reduce inflammation and as an analgesic to reduce pain in certain conditions.
Product Use:
It can also used to treat dysmenorrhea. It can treat inflammatory disorders such as musculoskeletal complaints, dental pain, arthritis, actinic keratosis, joint pain, acute pain and chronic pain caused by certain kinds of cancers. Traditional opinion proposes that diclofenac exerts its action via inhibition of prostaglandin synthesis by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) with relative equipotency. However, recent studies have shown that the pharmacologic activity of diclofenac goes beyond COX inhibition, and includes multimodal and, in some instances, novel mechanisms of action (MOA). For example, research suggests diclofenac can inhibit the thromboxane-prostanoid receptor, affect arachidonic acid release and uptake, inhibit lipoxygenase enzymes, and activate the nitric oxide–cGMP antinociceptive pathway. Other novel MOAs may include the inhibition of substrate P, inhibition of peroxisome proliferator activated receptor gamma (PPARγ), blockage of acid-sensing ion channels, alteration of interleukin-6 production, and inhibition of N-methyl-D-aspartate (NMDA) receptor hyperalgesia.
| Number | Cas | Name |
| 1 | 41859-67-0 | Bezafibrate |
| 2 | 62571-86-2 | Captopril |
| 3 | 113665-84-2 | Clopidogrel |
| 4 | 75847-73-3 | Enalapril |
| 5 | 49562-28-9 | Fenofibrate |
| 6 | 25812-30-0 | Gemfibrozil |
| 7 | 21187-98-4 | Glicalzide |
| 8 | 138402-11-6 | Irbesartan |
| 9 | 83915-83-7 | Lisinopril |
| 10 | 75330-75-5 | Lovastatin |
| 11 | 79902-63-9 | Simvastatin |
| 12 | 87333-19-5 | Ramipril |
| 13 | 144701-48-4 | Telmisartan |
| 14 | 13649-88-2 | Deflazacort |
| 15 | 50-02-2 | Dexamethasone |
| 16 | 2135-17-3 | Flumethasone |
| 17 | 53-03-2 | Prednisone |
About us
Zhejiang chemical import and export co., LTD. (zhejiang), formerly known as zhejiang branch of China national chemical import and export corporation, was established in December 1980. In 1988, he was transferred from Sinochem Corporation to be in charge of Zhejiang Provincial Department of Commerce and was renamed Zhejiang Chemical Import and Export Company. In 2003, the company changed its name to Zhejiang Chemical Import and Export Co., Ltd after the reform of state-owned enterprise shareholding system.
In 2008, it was incorporated into Zhejiang International Trade Group (one of the top 500 enterprises in China) and became the core member of the group's business circulation sector. The registered capital of the company is 72.5 million yuan, of which 38% are owned by the state and 62% are owned by employees.
There are 195 employees in the company, more than 79% of whom have bachelor's degree, 36% of whom are graduate students, and more than 90% of the salesmen have pharmaceutical and chemical background. The company is mainly engaged in the import and export trade of pharmaceutical raw materials and intermediates, dyes, pesticides, basic chemicals, fine chemicals, food and feed additives, pharmaceutical preparations and other products. The company has established close economic and trade relations with more than 100 countries and regions around the world. The company has wholly-owned subsidiaries Ruike International Trade Co., Ltd., Zhejiang Ruikai Chemical Co., Ltd., Zhejiang Fukai Import and Export Co., Ltd., joint-stock enterprise Zhejiang Aotokang Pharmaceutical Group Co., Ltd.
In recent years, especially since the establishment of the new team in 2019, the company has adhered to the development led by the party building, energized by reform, and improved efficiency by management. The company has shown a steady upward momentum of development. In 2020, the company achieved revenue of 3.337 billion yuan, total profit of 56.12 million yuan, total import and export of 450 million dollars.
In 2019, the company was rated as China Council for the Promotion of International Trade (CCPIT) Recommended Certification Enterprise, Top 100 International Pharmaceutical Enterprises -- a high-quality supplier and partner in the international market; In 2020, Zhejiang Provincial Department of Commerce and other units rated as the province's epidemic prevention and medical materials import outstanding contribution enterprise, Zhejiang Provincial Tax Bureau identified as the export tax rebate enterprises.
